Advertisement

Precision Medicine for Idiopathic Hypersomnia

Published:September 07, 2022DOI:https://doi.org/10.1016/j.jsmc.2022.06.016

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Sleep Medicine Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Roth B.
        Narcolepsy and hypersomnia.
        Karger, Basel (Switzerland)1980
      1. American Sleep Disorders Association. The international classification of sleep disorders. Diagnosis and coding manual 1990. American Academy of Sleep Medicine (Ed) Rochester (MN).

        • American Academy of Sleep Medicine
        The international classification of sleep disorders revised.
        American Academy of Sleep Medicine, Chicago2005
        • American Academy of Sleep Medicine
        The interna tional classification of sleep disorders.
        3rd edition. American Academy of Sleep Medicine, Darien (IL)2014
        • Ohayon M.
        • Reynolds C.I.
        • Dauvilliers Y.
        Excessive sleep duration and quality of life.
        Ann Neurol. 2013; 73: 785-794
        • Vernet C.
        • Leu-Semenescu S.
        • Buzare M.
        • et al.
        Sub jective symptoms in idiopathic hypersomnia: beyond excessive sleepiness.
        J Sleep Res. 2010; 19: 525-534
        • Lavault S.
        • Dauvilliers Y.
        • Drouot X.
        • et al.
        Benefit and risk of modafinil in idiopathic hypersomnia vs. nar colepsy with cataplexy.
        Sleep Med. 2011; 12: 550-556
        • Leu-Semenescu S.
        • Louis P.
        • Arnulf I.
        Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review.
        Sleep Med. 2016; 17: 38-44
        • Nittur N.
        • Konofal E.
        • Dauvilliers Y.
        • et al.
        Mazindol in narcolepsy and idiopathic and symptomatic hyper somnia refractory to stimulants: a long-term chart re view.
        Sleep Med. 2013; 14: 30-36
        • Sonka K.
        • Susta M.
        • Billiard M.
        Narcolepsy with and without cataplexy, idiopathic hypersomnia with and without long sleep time: a cluster analysis.
        Sleep Med. 2015; 16: 225-231
        • Anderson K.N.
        • Pilsworth S.
        • Sharples L.D.
        • et al.
        Idio- pathic hypersomnia: a study of 77 cases.
        Sleep. 2007; 30: 1274-1281
        • Mayer G.
        • Benes H.
        • Young P.
        • et al.
        Modafinil in the treatment of idiopathic hypersomnia without long sleep time—a randomized, double-blind, placebo- controlled study.
        J Sleep Res. 2015; 24: 74-81
        • Ali M.
        • Auger R.
        • Slocumb N.
        • et al.
        Idiopathic hyper somnia: clinical features and response to treatment.
        J Clin Sleep Med. 2009; 5: 562-568
        • Evangelista E.
        • Lopez R.
        • Barateau L.
        • et al.
        Alternative diagnostic criteria for idiopathic hypersomnia: a 32- hour protocol.
        Ann Neurol. 2018; 83: 235-247
        • Ozaki A.
        • Inoue Y.
        • Hayashida K.
        • et al.
        Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time: comparison between pa- tients on psychostimulants, drug-naive patients and the general Japanese population.
        Sleep Med. 2012; 13: 200-206
        • Bassetti C.
        • Aldrich M.
        Idiopathic hypersomnia. A se ries of 42 patients.
        Brain. 1997; 120 (Pubmed Partial Issue): 1423-1435
        • Pizza F.
        • Moghadam K.
        • Vandi S.
        • et al.
        Daytime continuous polysomnography predicts MSLT results in hypersomnias of central origin.
        J Sleep Res. 2013; 22: 32-40
        • Vernet C.
        • Arnulf I.
        Idiopathic hypersomnia with and without long sleep time: a controlled series of 75 pa tients.
        Sleep. 2009; 32: 753-759
        • Boucetta S.
        • Montplaisir J.
        • Zadra A.
        • et al.
        Altered regional cerebral blood flow in idiopathic hypersom- nia.
        Sleep. 2017; 40
        • Pizza F.
        • Ferri R.
        • Poli F.
        • et al.
        Polysomnographic study of nocturnal sleep in idiopathic hypersomnia without long sleep time.
        J Sleep Res. 2013; 22: 185-196
        • Vignatelli L.
        • D’Alessandro R.
        • Mosconi P.
        • et al.
        Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey.
        Sleep Med. 2004; 5: 467-475
        • Sasai T.
        • Inoue Y.
        • Komada Y.
        • et al.
        Comparison of clinical characteristics among narcolepsy with and without cataplexy and idiopathic hypersomnia without long sleep time, focusing on HLA- DRB1∗1501/DQB1∗0602 finding.
        Sleep Med. 2008; 10: 961-966
        • Barateau L.
        • Lopez R.
        • Arnulf I.
        • et al.
        Comorbidity between central disorders of hypersomnolence and immune-based disorders.
        Neurology. 2017; 88: 93-100
        • Barateau L.
        • Jaussent I.
        • Lopez R.
        • et al.
        Smoking, alcohol, drug use, abuse and dependence in narco- lepsy and idiopathic hypersomnia: a case-control study.
        Sleep. 2016; 39: 573-580
        • Trotti L.
        Waking up is the hardest thing I do all day: sleep inertia and sleep drunkenness.
        Sleep Med. 2017; 35: 78-84
        • Voderholzer U.
        • Backhaus J.
        • Hornyak M.
        • et al.
        A 19-h spontaneous sleep period in idiopathic central ner vous system hypersomnia.
        J Sleep Res. 1998; 7: 101-103
        • Rye D.B.
        • Bliwise D.L.
        • Parker K.
        • et al.
        Modulation of vigilance in the primary hypersomnias by endoge- nous enhancement of GABAA receptors.
        Sci Transl Med. 2012; 4: 161ra151
        • Trotti L.M.
        • Saini P.
        • Bliwise D.
        • et al.
        Clarithromycin in g-aminobutyric acid-related hypersomnolence: a ran domized, crossover trial.
        Ann Neurol. 2015; 78: 454-465
        • Vernet C.
        • Arnulf I.
        Narcolepsy with long sleep time: a specific entity?.
        Sleep. 2009; 32: 1229-1759
        • Vernet C.
        • Redolfi S.
        • Attali V.
        • et al.
        Residual sleepi- ness in obstructive sleep apnoea: phenotype and related symptoms.
        Eur Respir J. 2011; 38: 98-105
        • Billiard M.
        • Merle C.
        • Carlander B.
        • et al.
        Idiopathic hy persomnia.
        Psychiatry Clin Neurosci. 1998; 52: 125-129
        • Imbach L.L.
        • Valko P.O.
        • Li T.
        • et al.
        Increased sleep need and daytime sleepiness 6 months after trau- matic brain injury: a prospective controlled clinical trial.
        Brain. 2015; 138: 726-735
        • Ghergan A.
        • Coupaye M.
        • Leu-Semenescu S.
        • et al.
        Prevalence and phenotype of sleep disorders in 60 adults with Prader-Willi syndrome.
        Sleep. 2017; 40 (Pubmed Exact)https://doi.org/10.1093/sleep/zsx1162
        • American Academy of Sleep Medicine
        International classification of sleep disorders.
        in: Diag nostic and coding manual. 2nd edition. Amer ican Academy of Sleep Medicine, Westchester (IL)2005
        • Sforza E.
        • Gaudreau H.
        • Petit D.
        • et al.
        Homeostatic sleep regulation in patients with idiopathic hyper somnia.
        Clin Neurophysiol. 2000; 111: 277-282
        • Dang-Vu T.
        • Desseilles M.
        • Laureys S.
        • et al.
        Cerebral correlates of delta waves during non-REM sleep re visited.
        Neuroimage. 2005; 28: 14-21
        • Kanbayashi T.
        • Kodama T.
        • Kondo H.
        • et al.
        CSF hista mine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome.
        Sleep. 2009; 32: 181-187
        • Mignot E.
        • Lammers G.J.
        • Ripley B.
        • et al.
        The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
        Arch Neurol. 2002; 59: 1553-1562
        • Kanbayashi T.
        • Inoue Y.
        • Chiba S.
        • et al.
        CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hyper somnia.
        J Sleep Res. 2002; 11: 91-93
        • Peyron C.
        • Valentin F.
        • Bayard S.
        • et al.
        Melanin concentrating hormone in central hypersomnia.
        Sleep Med. 2011; 12: 768-772
        • Montplaisir J.
        • de Champlain J.
        • Young S.N.
        • et al.
        Nar colepsy and idiopathic hypersomnia: biogenic amines and related compounds in CSF.
        Neurology. 1982; 32: 1299-1302
        • Takei Y.
        • Komada Y.
        • Namba K.
        • et al.
        Differences in findings of nocturnal polysomnography and multiple sleep latency test between narcolepsy and idio- pathic hypersomnia.
        Clin Neurophysiol. 2012; 123: 137-141
        • Dauvilliers Y.
        • Evangelista E.
        • Lopez R.
        • et al.
        Absence of g-aminobutyric acid-a receptor potentiation in central hypersomnolence disorders.
        Ann Neurol. 2016; 80: 259-268
        • Nevsimalova S.
        • Blazejova K.
        • Illnerova H.
        • et al.
        A contribution to pathophysiology of idiopathic hy persomnia.
        Suppl Clin Neurophysiol. 2000; 53: 366-370
        • Materna L.
        • Halfter H.
        • Heidbreder A.
        • et al.
        Idiopathic hypersomnia patients revealed longer circadian period length in peripheral skin fibroblasts.
        Front Neurol. 2018; 9: 424
        • Saper C.B.
        • Scammell T.E.
        • Lu J.
        Hypothalamic regula tion of sleep and circadian rhythms.
        Nature. 2005; 437: 1257-1263
        • Hara J.
        • Beuckmann C.T.
        • Nambu T.
        • et al.
        Genetic ablation of orexin neurons in mice results in narco lepsy, hypophagia, and obesity.
        Neuron. 2001; 30: 345-354
        • Parmentier R.
        • Ohtsu H.
        • Djebbara-Hannas Z.
        • et al.
        Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock- out mice: evidence for the role of brain histamine in behavioral and sleep-wake control.
        J Neurosci. 2002; 22: 7695-7711
        • Petitjean F.
        • Sakai K.
        • Blondaux C.
        • et al.
        Hypersomnia by isthmic lesion in cat. II. Neurophysiological and pharmacological study.
        Brain Res. 1975; 88 ([in French]): 439-453
        • Lu J.
        • Jhou T.
        • Saper C.
        Identification of wake-active neurones in the ventral periaqueductal gray matter.
        J Neurosci. 2006; 26: 193-202
        • Lopez R.
        • Arnulf I.
        • Drouot X.
        • et al.
        French consensus. Management of patients with hypersomnia: which strategy?.
        Rev Neurol (Paris). 2017; 173: 8-18
        • Bastuji H.
        • Jouvet M.
        Successful treatment of idio pathic hypersomnia and narcolepsy with modafinil.
        Prog Neuropsychopharmacol Biol Psychiatry. 1988; 12: 695-700
        • Philip P.
        • Chaufton C.
        • Taillard J.
        • et al.
        Modafinil im proves real driving performance in patients with hy- persomnia: a randomized double-blind placebo- controlled crossover clinical trial.
        Sleep. 2014; 37: 483-487
        • Leu-Semenescu S.
        • Nittur N.
        • Golmard J.
        • et al.
        Effects of pitolisant, a histamine H3 inverse agonist, in drug- resistant idiopathic and symptomatic hypersomnia: a chart review.
        Sleep Med. 2014; 15: 681-687
        • Trotti L.M.
        • Saini P.
        • Koola C.
        • et al.
        Flumazenil for the treatment of refractory hypersomnolence: clinical experience with 153 patients.
        J Clin Sleep Med. 2016; 12: 1389-1394
        • Trotti L.
        • Saini P.
        • Freeman A.
        • et al.
        Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: clinical experi ence.
        J Psychopharmacol. 2014; 28: 697-702
        • Dauvilliers Y.
        • Bassetti C.
        • Lammers G.J.
        • et al.
        Pitoli- sant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
        Lancet Neurol. 2013; 12: 1068-1075
        • Dauvilliers Y.
        • Arnulf I.
        • Foldvary-Schaefer N.
        • Morse A.M.
        • Šonka K.
        • Thorpy M.J.
        • et al.
        Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
        Lancet Neurol. 2022; 21: 53-65
        • Inoue Y.
        • Tabata T.
        • Tsukimori N.
        Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long sleep time: a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study.
        Sleep Med. 2021; 80: 315-321
        • Nigam M.
        • Hippolyte A.
        • Dodet P.
        • Gales A.
        • Maranci J.B.
        • Al Youssef S.
        • Leu-Semenescu S.
        • Arnulf I.
        Sleeping through a pandemic: impact of COVID-19-related restrictions on narcolepsy and idiopathic hypersomnia.
        J Clin Sleep Med. 2022; 18: 255-263